Once again the MMJ Phytotech Ltd (ASX: MMJ) share price has been one of the biggest movers on the market this morning.
In early trade the pot stock’s share price has risen a massive 13%, bringing its month-to-date return to a staggering 169%.
Today’s announcement reveals that MMJ Phytotech’s partner HL Pharma Pty Ltd has received its medicinal cannabis import licence from the Australian Department of Health. This is a significant step towards supplying the Australian medicinal cannabis market.
The next step for the company will be to seek approval to supply its cannabidiol capsules to the Australian market via its Swiss subsidiary Satispharm.
This looks set to make it one of the first medicinal cannabis products available on the Australian market, giving the company a first mover advantage.
Should you invest?
Whilst I think the medical cannabis market could prove to be incredibly lucrative in the future, I think the share prices of MMJ Phytotech, Auscann Group Holdings Ltd (ASX: AC8), and Zelda Therapeutics Ltd (ASX: ZLD) may have run a little ahead of themselves right now.
Because of this I am a touch concerned that there could be a spot of profit taking in the near future that drives their share prices sharply lower.
For this reason I’m going to watch this exciting industry from the safety of the sidelines and focus on other areas of the market.
Alternatively, outside the healthcare industry are three hot growth shares at the top of their game. I'm tipping them for big things. Do you own them?
For many, blue chip stocks means stability, profitability and regular dividends, often full franked..
But knowing which blue chips to buy, and when, can often be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
If you’re expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you’ll be sorely disappointed. Not only are their dividends growing at a snail’s pace, their profits are under pressure too due to the increasing competitive environment.
The contrast to these “new breed” blue chips couldn’t be greater… especially the very real prospect of significant share price gains, something that’s looking less likely from the usual blue chip suspects.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia owns shares of Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.